Art Krieg moves from CEO post to CSO at Check­mate; In­di­v­ior breathes sigh of re­lief af­ter court rul­ing

→ Art Krieg is turn­ing in his spot in the CEO’s suite in ex­change for the CSO’s job at Check­mate Phar­ma­ceu­ti­cals. Bar­ry Labinger, for­mer CEO at Bio­thera, will take the top job as Krieg — who found­ed the com­pa­ny — spends a lot more time in the lab. Along with the switch-up in the ex­ec­u­tive of­fices, Check­mate al­so raised $22 mil­lion in a round led by Decheng Cap­i­tal. Ex­ist­ing in­vestors Sofinno­va, ven­Bio, and F-Prime all par­tic­i­pat­ed as well. “My ini­tial goal in found­ing Check­mate was to de­ter­mine if in­tra­tu­moral TLR9 ac­ti­va­tion could in­duce tu­mor re­gres­sion in an­ti-PD-1 re­frac­to­ry ad­vanced can­cer pa­tients,” Krieg com­ment­ed. “Now that we have achieved that goal, I am de­light­ed to turn over Check­mate’s lead­er­ship to Bar­ry, so that I can fo­cus my own ef­forts on the fur­ther sci­en­tif­ic de­vel­op­ment of our plat­form.” 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER